Home > Back to Publisher > Report Information

Partnering and M&A Agreements in Pharma and Biotech Yearbook 2010

Current Partnering
January 1, 2011
1100 Pages - SKU: WWV6077668

Abstract Table of Contents Search inside this report Related Reports

Partnering and M&A Agreements in Pharma and Biotech Yearbook 2010

The Partnering and M&A Deals in Pharma and Biotech Yearbook 2010 report provides comprehensive understanding and unprecedented access to the partnering and M&A deals and agreements entered into by the worlds leading healthcare companies during 2010.

Using this report, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report allows you to view all the partnering, alliances and M&A deals announced worldwide.

Chapter 1 provides an introduction to the report, whilst chapters 2 and 3 provide an overview of partnering and M&A trends, respectively, in 2010. The key partnering and M&A deals of 2010 are reviewed.

Chapter 4 analyzes the most active dealmakers in partnering and M&A during 2010.

Chapter 5 provides an overview of the leading deals for 2010 by headline value. The chapter provides covers both partnering and M&A dealmaking during the year.

The main body of the report is provided in chapters 6 and 7. Chapter 6 provides an in-depth review of every bigpharma company provides the reader with a breakdown of that company’s dealmaking during 2010 by deal type, stage of development and therapy focus. Each company entry is supplemented with a comprehensive listing of deals entered into during 2010, complete with a hyperlink to the deal record online. Where a contract document is available, this may also be found in the deal record online as filed with the SEC.

Chapter 7 provides a comprehensive directory of partnering and M&A activity during 2010. The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners’ negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

In summary, the report provides the reader with the resources necessary to make research and understand the partnerships, alliances and M&A deals of 2010.

Chapter 1 - Introduction
Chapter 2 - Overview of partnering activity in 2010: 2.1 Introduction; 2.2 Key partnering deals of 2010; 2.3 Partnering deals 2010; 2.4 Bigpharma partnering deals 2010; 2.5 Deals by therapy area in 2010; 2.6 Deals by stage development in 2010; 2.7 Deals by type in 2010
Chapter 3 - Overview of M&A activity in 2010: 3.1 Introduction; 3.2 Key M&A deals of 2010; 3.3 M&A deals of 2010; 3.4 Bigpharma M&A deals of 2010
Chapter 4 - Most active dealmakers in 2010: 4.1 Introduction; 4.2 M&A - most active in 2010; 4.2 Partnering - most active in 2010
Chapter 5 - Top deals by value in 2010: 5.1 Introduction; 5.2 Top partnering deals in 2010; 5.3 Top M&A deals in 2010
Chapter 5 - Bigpharma partnering in 2010: 5.1 How to use company partnering activity profiles; 5.2 Field definitions; 5.3 Company profiles and deal activity 2010
Chapter 6 - Partnering directory 2010: 6.1. Introduction; 6.2. Company A-Z; 6.3. By stage of development; 6.4. By deal type; 6.5. By therapy area
Chapter 7 - Submitting Opportunities to Potential Partners: 7.1 Introduction; 7.2 How to submit an opportunity; 7.3 Opportunity submission template; 7.4 Sending emails; 7.5 Face to face at partnering events; 7.6 Online submission forms; 7.7 Forthcoming partnering events in 2011
Chapter 8 - Resources: Further information; Methodology; About CurrentAgreements; About CurrentPartnering
TABLE OF FIGURES: Figure 1: Partnering activity 2005 to 2010; Figure 2: Bigpharma partnering activity 2005 to 2010; Figure 3: Partnering activity by therapy focus, 2008 to 2010; Figure 4: Partnering activity by stage of development, 2008 to 2010; Figure 5: Partnering activity by deal type, 2008 to 2010; Figure 6: M&A activity 2005 to 2010; Figure 7: Bigpharma M&A activity 2005 to 2010; Figure 8: Leading Bigpharma M&A companies, 2010; Figure 9: Bigpharma M&A activity - top 50 by pharma sales; Figure 10: Leading Bigpharma partnering companies, 2010; Figure 11: Bigpharma partnering activity - top 50 by pharma sales; Figure 12: Leading partnering deals by value, 2010; Figure 13: Leading M&A deals involving bigpharma by value, 2010; Figure 14: Company profile template and definitions used in report; Figure 15: Abbott partnering deals in 2010; Figure 16: Abbott M&A deals in 2010; Figure 17: Actavis partnering deals in 2010; Figure 18: Actavis M&A deals in 2010; Figure 19: Alcon partnering deals in 2010; Figure 20: Alcon M&A deals in 2010; Figure 21: Allergan partnering deals in 2010; Figure 22: Allergan M&A deals in 2010; Figure 23: Amgen partnering deals in 2010; Figure 24: Amgen M&A deals in 2010; Figure 25: Apotex partnering deals in 2010; Figure 26: Apotex M&A deals in 2010; Figure 27: Astellas partnering deals in 2010; Figure 28: Astellas M&A deals in 2010; Figure 29: AstraZeneca partnering deals in 2010; Figure 30: AstraZeneca M&A deals in 2010; Figure 31: Baxter partnering deals in 2010; Figure 32: Baxter M&A deals in 2010; Figure 33: Bayer partnering deals in 2010; Figure 34: Bayer M&A deals in 2010; Figure 35: Biogen Idec partnering deals in 2010; Figure 36: Biogen Idec M&A deals in 2010; Figure 37: Boehringer Ingelheim partnering deals in 2010; Figure 38: Boehringer Ingelheim M&A deals in 2010; Figure 39: Bristol-Myers Squibb partnering deals in 2010; Figure 40: Bristol-Myers Squibb M&A deals in 2010; Figure 41: Celgene partnering deals in 2010; Figure 42: Celgene M&A deals in 2010; Figure 43: Cephalon partnering deals in 2010; Figure 44: Cephalon M&A deals in 2010; Figure 45: Chugai partnering deals in 2010; Figure 46: Chugai M&A deals in 2010; Figure 47: CSL partnering deals in 2010; Figure 48: CSL M&A deals in 2010; Figure 49: Daiichi Sankyo partnering deals in 2010; Figure 50: Daiichi Sankyo M&A deals in 2010; Figure 51: Dainippon Sumitomo partnering deals in 2010; Figure 52: Dainippon Sumitomo M&A deals in 2010; Figure 53: Eisai partnering deals in 2010; Figure 54: Eisai M&A deals in 2010; Figure 55: Eli Lilly partnering deals in 2010; Figure 56: Eli Lilly M&A deals in 2010; Figure 57: Forest partnering deals in 2010; Figure 59: Genzyme partnering deals in 2010; Figure 60: Genzyme M&A deals in 2010; Figure 61: Gilead Sciences partnering deals in 2010; Figure 62: Gilead M&A deals in 2010; Figure 63: GlaxoSmithKline partnering deals in 2010; Figure 64: GlaxoSmithKline M&A deals in 2010; Figure 65: Hospira partnering deals in 2010; Figure 66: Hospira M&A deals in 2010; Figure 67: Johnson & Johnson partnering deals in 2010; Figure 68: Johnson & Johnson M&A deals in 2010; Figure 69: Kyowa Hakko Kirin partnering deals in 2010; Figure 70: Kyowa Hakko Kirin M&A deals in 2010; Figure 71: Lundbeck partnering deals in 2010; Figure 72: Lundbeck M&A deals in 2010; Figure 73: Meda partnering deals in 2010; Figure 74: Meda M&A deals in 2010; Figure 75: Menarini partnering deals in 2010; Figure 76: Menarini M&A deals in 2010; Figure 77: Merck & Co partnering deals in 2010; Figure 78: Merck & Co M&A deals in 2010; Figure 79: Merck KgaA partnering deals in 2010; Figure 80: Merck KgaA M&A deals in 2010; Figure 81: Mitsubishi Tanabe partnering deals in 2010; Figure 82: Mitsubishi Tanabe M&A deals in 2010; Figure 83: Mylan partnering deals in 2010; Figure 84: Mylan M&A deals in 2010; Figure 85: Novartis partnering deals in 2010; Figure 86: Novartis M&A deals in 2010; Figure 87: Novo Nordisk partnering deals in 2010; Figure 88: Novo Nordisk M&A deals in 2010; Figure 89: Nycomed partnering deals in 2010; Figure 90: Nycomed M&A deals in 2010; Figure 91: Otsuka partnering deals in 2010; Figure 92: Otsuka M&A deals in 2010; Figure 93: Pfizer partnering deals in 2010; Figure 94: Pfizer M&A deals in 2010; Figure 95: Ratiopharm partnering deals in 2010; Figure 96: Ratiopharm M&A deals in 2010; Figure 97: Roche partnering deals in 2010; Figure 98: Roche M&A deals in 2010; Figure 99: Sanofi-Aventis partnering deals in 2010; Figure 100: Sanofi-Aventis M&A deals in 2010; Figure 101: Servier partnering deals in 2010; Figure 102: Servier M&A deals in 2010; Figure 103: Shionogi partnering deals in 2010; Figure 104: Shionogi M&A deals in 2010; Figure 105: Shire partnering deals in 2010; Figure 106: Shire M&A deals in 2010; Figure 107: Takeda partnering deals in 2010; Figure 108: Takeda M&A deals in 2010; Figure 109: Teva partnering deals in 2010; Figure 110: Teva M&A deals in 2010; Figure 111: UCB partnering deals in 2010; Figure 112: UCB M&A deals in 2010; Figure 113: Watson partnering deals in 2010; Figure 114: Watson M&A deals in 2010; Figure 115: Typical partnering opportunity submission template; Figure 116: Online partnering resources

Partnering and M&A Agreements in Pharma and Biotech Yearbook 2010

Share this report

Other tasks

Research Assistance

Related Markets

Research & Development Reports

Free Alert Me service